Coeptis Total Liab from 2010 to 2024

COEPW Stock  USD 0.02  0  19.50%   
Coeptis Therapeutics Total Liabilities yearly trend continues to be fairly stable with very little volatility. Total Liabilities will likely drop to about 2.7 M in 2024. Total Liabilities is the total amount of all liabilities that Coeptis Therapeutics Holdings has, including both short-term and long-term liabilities. View All Fundamentals
 
Total Liabilities  
First Reported
2004-09-30
Previous Quarter
4.5 M
Current Value
M
Quarterly Volatility
M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Coeptis Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Coeptis Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 719.4 K, Other Operating Expenses of 41.3 M or Total Operating Expenses of 41.3 M, as well as many indicators such as Price To Sales Ratio of 5.2 K, Dividend Yield of 0.0 or PTB Ratio of 4.43. Coeptis financial statements analysis is a perfect complement when working with Coeptis Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Coeptis Therapeutics Correlation against competitors.
For more information on how to buy Coeptis Stock please use our How to Invest in Coeptis Therapeutics guide.

Latest Coeptis Therapeutics' Total Liab Growth Pattern

Below is the plot of the Total Liab of Coeptis Therapeutics Holdings over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. Coeptis Therapeutics' Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Coeptis Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Liab10 Years Trend
Slightly volatile
   Total Liab   
       Timeline  

Coeptis Total Liab Regression Statistics

Arithmetic Mean1,398,368
Geometric Mean470,472
Coefficient Of Variation135.09
Mean Deviation1,636,010
Median155,852
Standard Deviation1,889,084
Sample Variance3.6T
Range5.3M
R-Value0.72
Mean Square Error1.9T
R-Squared0.52
Significance0
Slope303,670
Total Sum of Squares50T

Coeptis Total Liab History

20242.7 M
20233.6 M
20223.1 M
20214.4 M
20205.4 M
2011155.9 K
2010310.9 K

About Coeptis Therapeutics Financial Statements

Coeptis Therapeutics investors use historical fundamental indicators, such as Coeptis Therapeutics' Total Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Coeptis Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Liabilities3.6 M2.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Coeptis Stock Analysis

When running Coeptis Therapeutics' price analysis, check to measure Coeptis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coeptis Therapeutics is operating at the current time. Most of Coeptis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Coeptis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coeptis Therapeutics' price. Additionally, you may evaluate how the addition of Coeptis Therapeutics to your portfolios can decrease your overall portfolio volatility.